NCT04405570View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

February 21, 2021

Study Completion Date

February 21, 2021

Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
DRUG

Molnupiravir 200 mg

Oral capsule of molnupiravir

DRUG

Molnupiravir 400 mg

Oral capsule of molnupiravir

DRUG

Molnupiravir 800 mg

Oral capsule of molnupiravir

DRUG

Placebo (PBO)

placebo oral capsule

Trial Locations (10)

27157

Wake Forest Baptist Medical Center, Winston-Salem

27599

University of North Carolina School of Medicine, Chapel Hill

27710

Duke University Medical Center, Durham

33012

Indago Research and Health Center, Inc., Hialeah

70115

NOLA Research Works, LLC, New Orleans

75126

Care United Research, LLC, Forney

91325

Valley Clinical Trials, Inc., Northridge

92399

Southern California Emergency Medicine, Yucaipa

93030

FOMAT Medical Research, Oxnard

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ridgeback Biotherapeutics, LP

INDUSTRY

NCT04405570 - Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | Biotech Hunter | Biotech Hunter